Sudarshan Pharma Industries Ltd

📊 Sudarshan Pharma: Rs.1,500 Cr FCCB Raise, Standalone Total Income Rs.26,686.17 lakhs & FCCB/Warrant Conversions

- Standalone total income: Rs. 26,686.17 lakhs (quarter ended 30 Sep 2026)

- Standalone net profit: Rs. 779.51 lakhs (quarter ended 30 Sep 2026)

- Consolidated total income: Rs. 39,454.00 lakhs (half year ended 30 Sep 2026)

- Consolidated net profit from continuing operations: Rs. 1,338.97 lakhs (half year ended 30 Sep 2026)

- Board consented to raise funds up to Rs.1,500 Crores by issuing FCCBs and other securities

- Approved issue of up to U.S.$20,000,000 8.00% senior unsecured FCCBs due 2029

- Allotted U.S.$10,000,000 aggregate value of FCCBs

- FCCB conversion: 48,11,730 equity shares allotted for FCCBs worth USD 15,00,000 at Rs.30.19

- Promoter warrant conversion: 90,00,000 equity shares allotted at Rs.16.98 each (9,00,000 warrants)

- Sudarshan USA incorporated w.e.f. 5th June, 2026 as wholly-owned subsidiary